Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Corvus Pharmaceuticals Inc

Current price
1.36 USD -0.14 USD (-9.33%)
Last closed 1.47 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 75 029 056 USD
Yield for 12 month +27.10 %
21.11.2021 - 28.11.2021

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California. Address: 863 Mitten Road, Burlingame, CA, United States, 94010

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

7.63 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-151 000 USD

Last Year

-367 000 USD

Current Quarter

-28 000 USD

Last Quarter

-30 000 USD

Key Figures CRVS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -23 178 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -25.63 %
PEG Ratio
Return On Equity TTM -57.02 %
Wall Street Target Price 7.63 USD
Revenue TTM
Book Value 0.79 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -0.56 USD
Diluted Eps TTM -0.56 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CRVS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CRVS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CRVS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -2.1179
Price Book MRQ 1.9395

Financials CRVS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CRVS

For 52 weeks

0.98 USD 4.19 USD
50 Day MA 2.01 USD
Shares Short Prior Month 1 493 650
200 Day MA 1.88 USD
Short Ratio 5.82
Shares Short 1 397 624
Short Percent 3.79 %

Dynamics of changes in the value of assets




411.84 USD Microsoft Corporation -5.76 (-1.38%)
Detailed analytics

ETF funds



208.40 CHF iShares MDAX UCITS ETF (DE) -12.16 (-5.06%)
Detailed analytics



2205.6 USD Gold +35.66 (+1.64%)
Detailed analytics